Product Overview

Acyclovir 200 mg is a generic antiviral tablet manufactured by Healing Pharma, India. Each strip contains ten tablets, each delivering 200 milligrams of the active ingredient acyclovir. The product is offered in pack sizes of 50, 100, or 200 tablets, providing flexibility for patients managing acute chickenpox outbreaks or chronic herpes simplex virus (HSV) infections. Healing Pharma adheres to stringent manufacturing practices that meet Indian Central Drugs Standard Control Organization requirements and are consistent with international pharmacopeial standards, ensuring each batch delivers the declared potency and purity. This medication is specifically indicated for the treatment of chickenpox (varicella) and for the management of initial and recurrent episodes of oral and genital herpes. References to authoritative sources such as the U.S. Food and Drug Administration and the National Library of Medicine confirm its established role in clinical practice.

What is Acyclovir 200 mg

Acyclovir belongs to the class of synthetic purine nucleoside analogues. After oral administration, the drug is absorbed through the gastrointestinal tract and undergoes selective phosphorylation in virus‑infected cells, where a viral thymidine kinase converts it to acyclovir monophosphate, which is subsequently converted by cellular kinases to the active triphosphate form, acyclovir‑TP. This active metabolite competitively inhibits viral DNA polymerase, leading to premature termination of viral DNA strands while sparing host cellular enzymes due to their lower affinity for the analogue. The resulting antiviral effect is highly specific for HSV‑infected cells, which explains the drug’s long‑standing use in both treatment and suppression of herpes‑related conditions. Detailed mechanistic descriptions are available in peer‑reviewed literature indexed on PubMed and summarized by the World Health Organization.

Uses and Benefits

The therapeutic benefits of acyclovir 200 mg are most pronounced when the medication is initiated early in the course of a viral outbreak. In patients with primary chickenpox, oral administration can reduce the number of cutaneous lesions, accelerate re‑epithelialization, and shorten the duration of associated symptoms such as fever and pruritus, especially when dosing begins within 24 hours of rash onset. For herpes simplex infections, timely use can lessen the severity and duration of oral or genital lesions, decrease the risk of complications such as encephalitis, and lower the likelihood of transmitting the virus to sexual partners. In addition to episodic therapy, acyclovir 200 mg may be prescribed as suppressive treatment for patients with frequent recurrences, typically administered twice daily to reduce outbreak frequency by up to 50 percent in many clinical trials. The medication is also employed off‑label in certain immunocompromised populations to prevent disseminated HSV or varicella‑zoster infections, although dosage adjustments are required in these groups. Evidence of efficacy is documented in FDA drug labels and summarized by the MedlinePlus consumer portal.

How It Works

Acyclovir’s mechanism of action hinges on its selective activation within virus‑infected cells. The initial phosphorylation step is catalyzed by the viral thymidine kinase, which is absent or present at markedly lower levels in uninfected host cells. This results in a high intracellular concentration of acyclovir‑monophosphate only in infected cells, where subsequent cellular kinases convert it to acyclovir‑triphosphate. The active triphosphate competes with deoxyguanosine triphosphate (dGTP) for incorporation into the growing viral DNA chain. Once incorporated, acyclovir‑triphosphate lacks a 3′‑hydroxyl group, causing chain termination and preventing further DNA elongation. This selective inhibition leads to a pronounced reduction in viral replication while preserving normal cellular DNA synthesis. The pharmacokinetic profile — characterized by oral bioavailability of approximately 15‑30 percent and renal excretion of unchanged drug — necessitates dosing intervals that maintain therapeutic plasma concentrations. Comprehensive pharmacokinetic data can be found in the NIH Bookshelf and in FDA prescribing information.

Dosage Guidelines

Dosage of acyclovir 200 mg must be individualized based on the patient’s age, renal function, severity of infection, and concomitant medications. For adults experiencing primary chickenpox, the standard regimen is 800 mg taken orally five times daily for seven days; when only 200 mg tablets are available, this translates to one tablet five times daily, delivering the equivalent total daily dose. In the treatment of initial genital herpes, the recommended adult dosage is 200 mg taken orally five times daily for ten days. For recurrent genital herpes, the same dosing schedule can be used for five days at the first sign of prodromal symptoms, or a suppressive regimen of 200 mg twice daily may be prescribed for up to twelve months under medical supervision. Patients with impaired renal function require dose reduction; a common adjustment is 200 mg every 12 hours for those with a creatinine clearance below 25 mL/min. It is essential that patients do not exceed the prescribed amount and that they complete the full course even if symptoms improve early. Any change to the dosing schedule should be discussed with a qualified healthcare professional.

Side Effects

Most patients tolerate acyclovir 200 mg well, but like all pharmaceutical agents, it can be associated with adverse effects. Common, generally mild side effects include nausea, vomiting, diarrhea, abdominal discomfort, headache, dizziness, and transient fatigue. Rare but clinically significant adverse reactions include hypersensitivity responses such as rash, pruritus, or angioedema, as well as neuropsychiatric manifestations like confusion, hallucinations, or seizures, particularly in individuals with pre‑existing neurological disorders or severe renal impairment. Elevations in serum creatinine have been reported in patients with underlying kidney disease, underscoring the importance of renal monitoring during therapy. If any signs of an allergic reaction develop — such as swelling of the face, lips, or throat, or difficulty breathing — immediate medical attention is required. For a complete list of reported adverse events, consult the FDA drug label, which is publicly accessible through the agency’s Drug Label Information portal.

Warnings and Precautions

Prior to initiating therapy with acyclovir 200 mg, clinicians should assess renal function, electrolyte status, and potential drug interactions. The medication is contraindicated in patients with a known hypersensitivity to acyclovir or any excipients present in the formulation. Caution is advised in immunocompromised patients, who may be at increased risk for severe herpes zoster or disseminated infections; dose modifications or alternative antiviral agents may be necessary. Concomitant use of other nephrotoxic drugs, such as non‑steroidal anti‑inflammatory medications or certain antibiotics, can increase the risk of renal impairment, warranting dose adjustment or careful monitoring. Pregnant women should use acyclovir only when the expected benefit justifies the potential risk, and breastfeeding mothers should discuss feeding options with their physician, as the drug is excreted in low amounts in milk. Patients are encouraged to maintain adequate hydration and to avoid excessive alcohol consumption, both of which can affect renal clearance. Individuals with a history of gout or those taking probenecid should monitor uric acid levels, as the combination can elevate serum urate. Finally, healthcare providers should counsel patients to report any new or worsening symptoms promptly.

Frequently Asked Questions

Can acyclovir 200 mg be used to treat shingles?
Yes. Although the 200 mg strength is primarily indicated for chickenpox and HSV infections, it can be part of a higher‑dose regimen for shingles when prescribed by a clinician. Typical shingles therapy involves 800 mg taken five times daily, which would equate to four 200 mg tablets per dose.

How quickly does acyclovir start working?
When therapy is begun at the first sign of a viral outbreak, acyclovir begins to inhibit viral replication within a few hours. Many patients experience a reduction in lesion formation and pain within 24‑48 hours, highlighting the importance of early intervention.

Is it safe to take acyclovir with other medications?
Acyclovir has a low potential for drug‑drug interactions, but caution is warranted when used alongside other nephrotoxic agents or medications that affect renal function. Patients should provide a complete medication list to their healthcare provider to evaluate possible interactions.

What should I do if I miss a dose?
If a dose is missed, it should be taken as soon as remembered, provided there is sufficient time before the next scheduled dose. If it is near the time of the next dose, the missed dose should be skipped and the regular dosing schedule resumed. Doubling the dose is not recommended.

Can acyclovir prevent recurrent herpes outbreaks?
Yes. In addition to episodic treatment, acyclovir can be used as suppressive therapy — typically 200 mg twice daily — to reduce the frequency of genital herpes recurrences. This regimen is usually continued for up to one year and should be discussed with a physician to determine suitability.

For additional scientific context, refer to resources such as the MedlinePlus drug entry, the NIH Bookshelf, and the World Health Organization guidelines on antiviral therapy.

Related Products

• Tretinoin 0.025% Cream (TRETINOIN)
• Azelax Cream (Azelaic Acid)
• Tretinoin 0.1% Cream (Tretinoin)
• Tretinoin Cream
• Tretinoin 0.05% Cream (TRETINOIN)
• Accufine 40 mg (Isotretinoin)
• Accufine 30 mg (Isotretinoin)
• Tretiheal 0.025% Cream (Tretinoin)
• Tretiheal 0.05% Cream (Tretinoin)
• Tretiheal 0.1% Cream (Tretinoin)
• Accufine 5 mg (Isotretinoin)
• Accufine 20 mg Softgel Capsule (Isotretinoin)